Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.

Gay, Francesca; Cerrato, Chiara; Teresa Petrucci, Maria; Zambello, Renato; Gamberi, Barbara; Ballanti, Stelvio; Omedè, Paola; Palmieri, Salvatore; Troia, Rossella; Spada, Stefano; Gozzetti, Alessandro; Caravita, Tommaso; Spadano, Antonio; Palumbo, Antonio; Montefusco, Vittorio; Musto, Pellegrino; Cavo, Michèle; Boccadoro, Mario

doi:10.1200/jco.2019.37.15_suppl.8002

Public

Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.

Published in Journal of Clinical Oncology • May 20, 2019

Authors:

Francesca Gay

Chiara Cerrato

Maria Teresa Petrucci

Abstract

8002 Background: High and comparable rates of MRD negativity were seen in NDMM pts after 4 28-day induction cycles with KRd followed by ASCT and 4 KRd consolidation (KRd_ASCT_KRd) and after 12 KRd cycles (KRd12), showing the superiority of both regimens over KCd induction-ASCT-KCd consolidation (KCd...

Subject

Medicine

Carfilzomib

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!